Anticancer Drugs 2021

• Autore: Meegan Mary J
• Pubblicazione: Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
• Descrizione fisica: 1 online resource (594 p.)
• Soggetto topico: Chemistry; Research & information: general; Research and information: general
• Soggetto non controllato: 1,2,3-triazole; 1,3,4-oxadiazole; 3-amino-4'-guanidino; 3,4'-bis-guanidino; 5-fluoruracil; 7-deaza-4'-thioadenosine derivatives; acetamide; adamantane; ADC (antibody-drug conjugate); age; alkylated; anticancer; anticancer activity; anticancer agents; apoptosis; apoptosis induction; aromatase inhibitor; Bcl-2 inhibitors; benzenesulfonamides; benzimidazole; BRAF; breast cancer; cancer; cancer cell viability; cancer vaccine; CAR (chimeric antigen receptor); cardiotoxicity; carvedilol; cell cycle analysis; chalcone; chalcones; colony formation; combretastatin A-4; concentration-guided dosing; covalent binding; CovDock; cumulative dose; cyclophosphamide; cytotoxic activity; cytotoxic agents; cytotoxicity; designed multiple ligand; diphenyl ether; DNA fragmentation; docking; doxazosin; drug efflux; dual inhibitors; dual-targeting molecule; EGFR; ELISA; enantioselective synthesis; entrectinib; exportin-1; gastric adenocarcinoma; generic product; H1299; HDAC inhibitors; HER2; heterocyclic compound; histopathology; HL-60; HT-29 cells; hybrid compounds; hybrid molecule; hydrazide derivatives; imidazoles; Imiquimod; immunotherapy; in vitro; in vivo; indazole; Indole-based analogues; inflammation; interleukin-6; intramolecular hydrogen bond; isolation; kidney; larotrectinib; letrozole; MD simulations; MDA-MB-231 cells; mechanism prediction; miR-21; mitoxantrone; model informed dosing; MTT cytotoxic assay; MUC1; MUC16; mucin; multi-kinase inhibitor; multidrug resistance; n/a; NaMSA; nitrogen scaffolds; NTRK; nucleoside; oxidative stress; patent review; pemetrexed; phenstatin; phenyl pyridyl ether; physiologically based pharmacokinetics; protein kinase inhibitors; resin acid; solid/lipid nanoparticles; sorafenib; STAT inhibitors; synthesis; TDP1; testis; thieno[2,3-d][1,2,3]triazine; thiourea; thymidylate synthase; tissue-agnostic; Toll-Like Receptor; toxicity; Trk; Trk fusion; trypan blue assay; tryptophanol; tubulin polymerisation inhibitor; tumor spheroids; tyrosil-DNA-phosphodiesterase 1; urinary bladder; USFDA; xanthone
• Persona (resp. second.): O'BoyleNiamh M; MeeganMary J
• Sommario/riassunto: The Special Issue "Anticancer Drugs 2021" of Pharmaceuticals is focused on recent significant advances in the design, synthesis, molecular mechanism of action and therapeutic applications of anticancer drugs. This collection of preclinical research papers and reviews includes designed chemotherapeutic agents, targeted therapies and biological agents. The rationalization for the biological activity of these drugs is presented, which helps to guide the design of more effective agents. Structure-activity relationships, together with the biological context in which targets are selected for oncology drug development, are also considered.
• Titolo autorizzato: Anticancer Drugs 2021
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910576874303321
• Lo trovi qui: Univ. Federico II